Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer

被引:4
|
作者
Tharmalingam, H. [1 ]
Tsang, Y. M. [1 ]
Alonzi, R. [1 ]
Beasley, W. [2 ]
Taylor, N. J. [3 ]
McWilliam, A. [4 ]
Padhani, A. [3 ]
Choudhury, A. [4 ]
Hoskin, P. J. [1 ,4 ]
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] Christie NHS Fdn Trust, Christie Med Phys & Engn, Manchester, Lancs, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Univ Manchester, Fac Biol Med & Hlth, Div Canc Sci, Manchester, Lancs, England
关键词
ADT; MR radiomics; prostate cancer; GROWTH-FACTOR EXPRESSION; RADIOTHERAPY; SUPPRESSION; CARCINOMA; APOPTOSIS; TUMORS; MRI;
D O I
10.1016/j.clon.2021.12.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The benefits of neoadjuvant androgen deprivation therapy (nADT) in the management of intermediate- and high-risk prostate cancer patients have been well-established. The aim of this study was to identify radiomic prognostic features derived from routine anatomic magnetic resonance imaging (MRI) sequences that can predict the response of the prostate cancer to nADT. Materials and methods: Patients with intermediate- and high-risk prostate cancer (with one of clinical stage >= T2c, Gleason score >= 7 or presenting prostate-specific antigen >= 10) who received 3 months of ADT prior to radical external beam radiotherapy were enrolled into this study. The relative blood volume and the relative blood flow were used as dynamic MRI kinetic parameters to quantify vascular changes as responses to nADT. For all pre- and post-nADT data sets, a combination of T2-weighted and contrast-enhanced T1-weighted anatomic images were used to define regions of interest (ROI) as the dominant malignant nodules (DMNs) and the benign prostate (the entire prostate with the summed DMNs being subtracted). MRI textural radiomic features associated with prostate cancer response in the literature of energy and homogeneity were selected. Pyradiomics was used to extract textural features of the ROIs. A Wilcoxon signed-rank test was carried out to investigate if there were statistically significant differences in values of radiomic features between: (i) benign prostate ROI and DMN pre-nADT; (ii) pre- and post-nADT of benign prostate ROI; (iii) pre- and post-nADT of DMN. Changes in radiomic features and dynamic MRI kinetic parameters were correlated using the Spearman correlation test. Results: Twenty prostate cancer patients were recruited into the study. The median time between the first baseline scan and the first on-treatment scan was 91.5 days (range 82-105). One patient had no discernible tumour visible, leaving 19 patients with evaluable data for the analysis. Baseline homogeneity and energy values differed significantly between benign and malignant tissue (P < 0.01). In response to nADT, homogeneity and energy showed reciprocal changes, significantly increased in benign prostate while decreasing in the DMN. The reduction in tumour homogeneity and energy feature values showed a positive association with the decline in tumour blood flow and tumour blood volume induced by androgen deprivation as derived from dynamic MRI parameters. Conclusion: Energy and homogeneity radiomic features derived from MRI of benign and malignant prostate showed significant reciprocal changes in response to nADT. This study confirms the potential of these radiomic features to act as surrogate markers of tumour androgen sensitivity due to their strong association with ADT-induced physiological effects in prostate tumours. (C) 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E246 / E253
页数:8
相关论文
共 50 条
  • [1] Validation and Reproducibility of Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with High-risk Prostate Cancer
    Tharmalingam, H.
    Beasley, W.
    Alonzi, R.
    McWilliam, A.
    Hoskin, P.
    Choudhury, A.
    [J]. CLINICAL ONCOLOGY, 2019, 31 (02) : E24 - E24
  • [2] Validation and physiological association of changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with high-risk prostate cancer.
    Tharmalingam, Hannah
    Beasley, William
    Alonzi, Roberto
    McWilliam, Alan
    Hoskin, Peter
    Choudhury, Ananya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision
    Castro Mendez, Lucas
    Martell, Kevin
    Crook, Juanita M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3820 - +
  • [4] Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States
    Falchook, Aaron D.
    Basak, Ramsankar
    Mohiuddin, Jahan J.
    Chen, Ronald C.
    [J]. JAMA ONCOLOGY, 2016, 2 (09) : 1236 - 1238
  • [5] Recent Trends in the Use of Androgen Deprivation Therapy with External Beam Radiation Therapy for Patients with Intermediate- and High-Risk Prostate Cancer
    Yang, D. D.
    Orio, P. F., III
    Nguyen, P. L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E151 - E152
  • [6] Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision Reply
    Jackson, William C.
    Hartman, Holly E.
    Dess, Robert T.
    Spratt, Daniel E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3823 - +
  • [7] Trends in Androgen Deprivation Therapy Use With Radiation for Intermediate- and High-Risk Prostate Cancer Across the United States
    Falchook, A.
    Mohiuddin, J. J.
    Chen, R. C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S45 - S45
  • [8] A Phase 1 study Combining Pexidartinib, Radiation Therapy, and Androgen Deprivation Therapy in Men With Intermediate- and High-Risk Prostate Cancer
    Hamid, Muhammad
    Heilbrun, Lance K.
    Maier, Jordan
    Devisetty, Kiran
    Connolly, Irene
    Kaufman, Isaac
    Dobson, Kimberlee
    Herroon, Mackenzie K.
    Smith, Daryn
    Sampson, Sandra
    Podgorski, Izabela
    Heath, Elisabeth I.
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2021, 6 (04)
  • [9] Focal therapy in intermediate- and high-risk prostate cancer
    Huebner, Nicolai A.
    Korn, Stephan
    Rajwa, Pawel
    Shariat, Shahrokh F.
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (04) : 247 - 250
  • [10] Focal therapy in intermediate- and high-risk prostate cancer
    Nicolai A. Huebner
    Stephan Korn
    Pawel Rajwa
    Shahrokh F. Shariat
    [J]. memo - Magazine of European Medical Oncology, 2023, 16 : 247 - 250